Signal from the log
ai3Bio
48 M$ · Series A · United States · Biotech
ai3Bio, à Watertown près de Boston, veut traiter les maladies auto-immunes en éliminant directement dans le corps les lymphocytes Th17 qui les entretiennent, soit par un ARN messager livré en nanoparticule, soit par un anticorps. Encore préclinique, sa série A est menée par UPMC Enterprises et Ziff Capital Partners.
Article
Announced on , logged by the watch of 29 September 2026.
- Operation
- Funding round
- Announced amount
- 48 M$
- Stage
- Series A
- Country
- United States
- Sector
- Biotech
What the log says
Editorial note, in French
Sujet traité. L'article donne les sources et la position de Bolus.
The investors
Led by UPMC Enterprises , Ziff Capital Partners , with Cockrell Interests , Tanis Ventures
Provenance
Source businesswire
Logged on 29 September 2026
Description Written in French during the watch run. Written during the watch run, after reading the issuer's press release or the source article.
Verification Amounts and fund names were double checked against the issuer's press release or an official filing.
What this status means
Article The operation led to an article, with its sources checked one by one.
The rule A signal is never removed from the log. A round set aside stays readable with its reason, because a collection you cannot reread is a collection you cannot correct.